{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:28:43Z","timestamp":1769599723707,"version":"3.49.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1K23DC014291"],"award-info":[{"award-number":["1K23DC014291"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s11764-022-01312-x","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T05:04:15Z","timestamp":1673586255000},"page":"4-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Special considerations in the design and implementation of pediatric otoprotection trials"],"prefix":"10.1007","volume":"17","author":[{"given":"David R.","family":"Freyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etan","family":"Orgel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Krailo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"1312_CR1","doi-asserted-by":"publisher","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","volume":"88","author":"S Ghosh","year":"2019","unstructured":"Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925.","journal-title":"Bioorg Chem"},{"issue":"19","key":"1312_CR2","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1200\/JCO.2011.39.1110","volume":"30","author":"PR Brock","year":"2012","unstructured":"Brock PR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012;30(19):2408\u201317.","journal-title":"J Clin Oncol"},{"key":"1312_CR3","doi-asserted-by":"crossref","unstructured":"van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev. 2016;(8):CD010181.","DOI":"10.1002\/14651858.CD010181.pub2"},{"issue":"4","key":"1312_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S2352-4642(21)00020-1","volume":"5","author":"DJ Moke","year":"2021","unstructured":"Moke DJ, et al. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study. Lancet Child Adolesc Health. 2021;5(4):274\u201383.","journal-title":"Lancet Child Adolesc Health"},{"issue":"34","key":"1312_CR5","doi-asserted-by":"publisher","first-page":"8588","DOI":"10.1200\/JCO.2004.00.5355","volume":"23","author":"KR Knight","year":"2005","unstructured":"Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23(34):8588\u201396.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1312_CR6","doi-asserted-by":"publisher","first-page":"e1229","DOI":"10.1542\/peds.2007-0178","volume":"120","author":"JG Gurney","year":"2007","unstructured":"Gurney JG, et al. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children\u2019s Oncology Group. Pediatrics. 2007;120(5):e1229\u201336.","journal-title":"Pediatrics"},{"issue":"6","key":"1312_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.2013.51.2038","volume":"32","author":"W Landier","year":"2014","unstructured":"Landier W, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales\u2013a report from the Children\u2019s Oncology Group. J Clin Oncol. 2014;32(6):527\u201334.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1312_CR8","first-page":"4053","volume":"121","author":"TM Brinkman","year":"2015","unstructured":"Brinkman TM, et al. Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: results from the St. Jude Lifetime Cohort Study Cancer. 2015;121(22):4053\u201361.","journal-title":"Jude Lifetime Cohort Study Cancer"},{"issue":"3","key":"1312_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/pbc.25804","volume":"63","author":"E Orgel","year":"2016","unstructured":"Orgel E, et al. Effect of sensorineural hearing loss on neurocognitive functioning in pediatric brain tumor survivors. Pediatr Blood Cancer. 2016;63(3):527\u201334.","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"1312_CR10","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1001\/jamaoncol.2020.2822","volume":"6","author":"JK Bass","year":"2020","unstructured":"Bass JK, et al. Association of hearing impairment with neurocognition in survivors of childhood cancer. JAMA Oncol. 2020;6(9):1363\u201371.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1312_CR11","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/AUD.0b013e3181c8e7b6","volume":"31","author":"YS Sininger","year":"2010","unstructured":"Sininger YS, Grimes A, Christensen E. Auditory development in early amplified children: factors influencing auditory-based communication outcomes in children with hearing loss. Ear Hear. 2010;31(2):166\u201385.","journal-title":"Ear Hear"},{"issue":"23","key":"1312_CR12","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2016.66.8822","volume":"34","author":"RD Frisina","year":"2016","unstructured":"Frisina RD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol. 2016;34(23):2712\u201320.","journal-title":"J Clin Oncol"},{"key":"1312_CR13","unstructured":"The Voice of the Patient Hyattsville, MD2018 [updated September 13, 2018. Available from: https:\/\/www.fda.gov\/media\/132522\/download"},{"issue":"11","key":"1312_CR14","doi-asserted-by":"publisher","first-page":"e28647","DOI":"10.1002\/pbc.28647","volume":"67","author":"E Orgel","year":"2020","unstructured":"Orgel E, et al. Assessment of provider perspectives on otoprotection research for children and adolescents: a Children\u2019s Oncology Group Cancer Control and Supportive Care Committee survey. Pediatr Blood Cancer. 2020;67(11):e28647.","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"1312_CR15","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/17425255.2020.1806235","volume":"16","author":"D Mukherjea","year":"2020","unstructured":"Mukherjea D, et al. Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity. Expert Opin Drug Metab Toxicol. 2020;16(10):965\u201382.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3S","key":"1312_CR16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1044\/2021_AJA-21-00006","volume":"30","author":"PS Steyger","year":"2021","unstructured":"Steyger PS. Mechanisms of aminoglycoside- and cisplatin-induced ototoxicity. Am J Audiol. 2021;30(3S):887\u2013900.","journal-title":"Am J Audiol"},{"issue":"4","key":"1312_CR17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1681\/ASN.V134858","volume":"13","author":"MS Park","year":"2002","unstructured":"Park MS, De Leon M, Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol. 2002;13(4):858\u201365.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"1312_CR18","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s10495-007-0082-8","volume":"12","author":"P Bragado","year":"2007","unstructured":"Bragado P, et al. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis. 2007;12(9):1733\u201342.","journal-title":"Apoptosis"},{"key":"1312_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fncel.2017.00338","volume":"11","author":"S Sheth","year":"2017","unstructured":"Sheth S, et al. Mechanisms of cisplatin-induced ototoxicity and otoprotection. Front Cell Neurosci. 2017;11:338.","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"1312_CR20","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1038\/s41598-018-22640-y","volume":"8","author":"W Yu","year":"2018","unstructured":"Yu W, et al. Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep. 2018;8(1):4306.","journal-title":"Sci Rep"},{"key":"1312_CR21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1312_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1179\/joc.2009.21.1.74","volume":"21","author":"OW Guthrie","year":"2009","unstructured":"Guthrie OW. DNA repair proteins and telomerase reverse transcriptase in the cochlear lateral wall of cisplatin-treated rats. J Chemother. 2009;21(1):74\u20139.","journal-title":"J Chemother"},{"issue":"3","key":"1312_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1159\/000099020","volume":"12","author":"G Laurell","year":"2007","unstructured":"Laurell G, et al. Effects of a single high dose of cisplatin on the melanocytes of the stria vascularis in the guinea pig. Audiol Neurootol. 2007;12(3):170\u20138.","journal-title":"Audiol Neurootol"},{"issue":"10","key":"1312_CR24","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/dvdy.24150","volume":"243","author":"EL Slattery","year":"2014","unstructured":"Slattery EL, et al. Cisplatin exposure damages resident stem cells of the mammalian inner ear. Dev Dyn. 2014;243(10):1328\u201337.","journal-title":"Dev Dyn"},{"issue":"1","key":"1312_CR25","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/s41467-017-01837-1","volume":"8","author":"AM Breglio","year":"2017","unstructured":"Breglio AM, et al. Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun. 2017;8(1):1654.","journal-title":"Nat Commun"},{"issue":"1","key":"1312_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/pbc.24138","volume":"59","author":"A Yancey","year":"2012","unstructured":"Yancey A, et al. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012;59(1):144\u20138.","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"1312_CR27","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.ejca.2003.08.009","volume":"40","author":"Y Li","year":"2004","unstructured":"Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004;40(16):2445\u201351.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1312_CR28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41397-019-0113-1","volume":"20","author":"E Clemens","year":"2020","unstructured":"Clemens E, et al. Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: the International PanCareLIFE study. Pharmacogenomics J. 2020;20(2):294\u2013305.","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"1312_CR29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/cpt.1483","volume":"106","author":"BI Drogemoller","year":"2019","unstructured":"Drogemoller BI, et al. Pharmacogenomics of cisplatin-induced ototoxicity: successes, shortcomings, and future avenues of research. Clin Pharmacol Ther. 2019;106(2):350\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1312_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41698-021-00178-z","volume":"5","author":"AJM Meijer","year":"2021","unstructured":"Meijer AJM, et al. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precis Oncol. 2021;5(1):64.","journal-title":"NPJ Precis Oncol"},{"key":"1312_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejca.2020.07.019","volume":"138","author":"T Langer","year":"2020","unstructured":"Langer T, et al. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: results of the European PanCareLIFE cohort study. Eur J Cancer. 2020;138:212\u201324.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1312_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pbc.21875","volume":"52","author":"MJ Lewis","year":"2009","unstructured":"Lewis MJ, et al. Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer. 2009;52(3):387\u201391.","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"1312_CR33","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1200\/JCO.2011.36.9744","volume":"30","author":"I Qaddoumi","year":"2012","unstructured":"Qaddoumi I, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol. 2012;30(10):1034\u201341.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1312_CR34","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/sj.bmt.1701391","volume":"22","author":"SK Parsons","year":"1998","unstructured":"Parsons SK, et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant. 1998;22(7):669\u201374.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1312_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/mpo.2950170110","volume":"17","author":"DA Walker","year":"1989","unstructured":"Walker DA, et al. Enhanced cis-platinum ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation. Med Pediatr Oncol. 1989;17(1):48\u201352.","journal-title":"Med Pediatr Oncol"},{"issue":"3","key":"1312_CR36","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/00005537-199703000-00028","volume":"107","author":"S Kohn","year":"1997","unstructured":"Kohn S, et al. Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope. 1997;107(3):407\u20138.","journal-title":"Laryngoscope"},{"issue":"17","key":"1312_CR37","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.21037\/atm-21-2508","volume":"9","author":"X Lin","year":"2021","unstructured":"Lin X, et al. Experimental animal models of drug-induced sensorineural hearing loss: a narrative review. Ann Transl Med. 2021;9(17):1393.","journal-title":"Ann Transl Med"},{"issue":"4","key":"1312_CR38","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1089\/zeb.2016.1412","volume":"14","author":"DW Todd","year":"2017","unstructured":"Todd DW, et al. A fully automated high-throughput zebrafish behavioral ototoxicity assay. Zebrafish. 2017;14(4):331\u201342.","journal-title":"Zebrafish"},{"issue":"17","key":"1312_CR39","doi-asserted-by":"publisher","first-page":"7700","DOI":"10.1021\/acs.jmedchem.8b00669","volume":"61","author":"RA Hazlitt","year":"2018","unstructured":"Hazlitt RA, et al. Development of second-generation CDK2 inhibitors for the prevention of cisplatin-induced hearing loss. J Med Chem. 2018;61(17):7700\u20139.","journal-title":"J Med Chem"},{"key":"1312_CR40","doi-asserted-by":"crossref","unstructured":"Ingersoll MA, et al. BRAF inhibition protects against hearing loss in mice. Sci Adv. 2020;6(49).","DOI":"10.1126\/sciadv.abd0561"},{"key":"1312_CR41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/978-1-4939-3615-1_22","volume":"1427","author":"T Teitz","year":"2016","unstructured":"Teitz T, et al. Development of cell-based high-throughput chemical screens for protection against cisplatin-induced ototoxicity. Methods Mol Biol. 2016;1427:419\u201330.","journal-title":"Methods Mol Biol"},{"key":"1312_CR42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.heares.2019.02.006","volume":"375","author":"K Fernandez","year":"2019","unstructured":"Fernandez K, et al. An optimized, clinically relevant mouse model of cisplatin-induced ototoxicity. Hear Res. 2019;375:66\u201374.","journal-title":"Hear Res"},{"issue":"13","key":"1312_CR43","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S1470-2045(15)00248-X","volume":"16","author":"HH Wong","year":"2015","unstructured":"Wong HH, Halford S. Dose-limiting toxicity and maximum tolerated dose: still fit for purpose? Lancet Oncol. 2015;16(13):1287\u20138.","journal-title":"Lancet Oncol"},{"key":"1312_CR44","doi-asserted-by":"crossref","unstructured":"Filloon TG. Estimating the minimum therapeutically effective dose of a compound via regression modelling and percentile estimation. Stat Med. 1995;14(9\u201310):925\u201332; discussion 33.","DOI":"10.1002\/sim.4780140911"},{"issue":"1","key":"1312_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12885-021-07782-z","volume":"21","author":"J Fraisse","year":"2021","unstructured":"Fraisse J, et al. Optimal biological dose: a systematic review in cancer phase I clinical trials. BMC Cancer. 2021;21(1):60.","journal-title":"BMC Cancer"},{"issue":"1","key":"1312_CR46","first-page":"309","volume":"6","author":"LL Muldoon","year":"2000","unstructured":"Muldoon LL, et al. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res. 2000;6(1):309\u201315.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1312_CR47","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11060-014-1657-1","volume":"121","author":"LL Muldoon","year":"2015","unstructured":"Muldoon LL, et al. N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models. J Neurooncol. 2015;121(3):433\u201340.","journal-title":"J Neurooncol"},{"issue":"6","key":"1312_CR48","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1159\/000241896","volume":"14","author":"X Wang","year":"2009","unstructured":"Wang X, et al. Dose-dependent sustained release of dexamethasone in inner ear cochlear fluids using a novel local delivery approach. Audiol Neurootol. 2009;14(6):393\u2013401.","journal-title":"Audiol Neurootol"},{"issue":"1","key":"1312_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","volume":"37","author":"A Al Shoyaib","year":"2019","unstructured":"Al Shoyaib A, Archie SR, Karamyan VT. Intraperitoneal route of drug administration: should it be used in experimental animal studies? Pharm Res. 2019;37(1):12.","journal-title":"Pharm Res"},{"issue":"2","key":"1312_CR50","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1158\/1078-0432.CCR-06-2289","volume":"14","author":"TM Harned","year":"2008","unstructured":"Harned TM, et al. Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. Clin Cancer Res. 2008;14(2):533\u201340.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1312_CR51","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1124\/jpet.103.063347","volume":"309","author":"EA Neuwelt","year":"2004","unstructured":"Neuwelt EA, et al. Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther. 2004;309(2):594\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1312_CR52","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1124\/jpet.105.087601","volume":"314","author":"DT Dickey","year":"2005","unstructured":"Dickey DT, et al. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther. 2005;314(3):1052\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2 Pt 1","key":"1312_CR53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/000348948109000208","volume":"90","author":"SK Juhn","year":"1981","unstructured":"Juhn SK, Rybak LP, Prado S. Nature of blood-labyrinth barrier in experimental conditions. Ann Otol Rhinol Laryngol. 1981;90(2 Pt 1):135\u201341.","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"4","key":"1312_CR54","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10162-020-00759-y","volume":"21","author":"BK Gersten","year":"2020","unstructured":"Gersten BK, et al. Ototoxicity and platinum uptake following cyclic administration of platinum-based chemotherapeutic agents. J Assoc Res Otolaryngol. 2020;21(4):303\u201321.","journal-title":"J Assoc Res Otolaryngol"},{"issue":"5","key":"1312_CR55","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s10637-020-00918-1","volume":"38","author":"V Viglietta","year":"2020","unstructured":"Viglietta V, et al. Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients. Invest New Drugs. 2020;38(5):1463\u201371.","journal-title":"Invest New Drugs"},{"issue":"4","key":"1312_CR56","first-page":"286","volume":"17","author":"SV Prykhozhij","year":"2017","unstructured":"Prykhozhij SV, Caceres L, Berman JN. New developments in CRISPR\/Cas-based functional genomics and their implications for research using zebrafish. Curr Gene Ther. 2017;17(4):286\u2013300.","journal-title":"Curr Gene Ther"},{"key":"1312_CR57","doi-asserted-by":"crossref","unstructured":"Wertman JN, et al. The identification of dual protective agents against cisplatin-induced oto- and nephrotoxicity using the zebrafish model. Elife. 2020;9.","DOI":"10.7554\/eLife.56235"},{"issue":"1","key":"1312_CR58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1470-2045(16)30625-8","volume":"18","author":"DR Freyer","year":"2017","unstructured":"Freyer DR, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(1):63\u201374.","journal-title":"Lancet Oncol"},{"issue":"25","key":"1312_CR59","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1056\/NEJMoa1801109","volume":"378","author":"PR Brock","year":"2018","unstructured":"Brock PR, et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N Engl J Med. 2018;378(25):2376\u201385.","journal-title":"N Engl J Med"},{"key":"1312_CR60","doi-asserted-by":"crossref","unstructured":"Minasian LM, et al. Prevention of cisplatin-induced hearing loss in children: informing the design of future clinical trials. Cancer Med. 2018.","DOI":"10.1002\/cam4.1563"},{"issue":"2","key":"1312_CR61","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S2352-4642(19)30336-0","volume":"4","author":"DR Freyer","year":"2020","unstructured":"Freyer DR, et al. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. Lancet Child Adolesc Health. 2020;4(2):141\u201350.","journal-title":"Lancet Child Adolesc Health"},{"key":"1312_CR62","unstructured":"FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors. 2022 [updated September 20, 2022."},{"issue":"2","key":"1312_CR63","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.joto.2017.12.001","volume":"13","author":"RJ Schroeder 2nd","year":"2018","unstructured":"Schroeder RJ 2nd, et al. Pharmacokinetics of sodium thiosulfate in Guinea pig perilymph following middle ear application. J Otol. 2018;13(2):54\u20138.","journal-title":"J Otol"},{"issue":"1","key":"1312_CR64","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000441833","volume":"21","author":"R Fernandez","year":"2016","unstructured":"Fernandez R, et al. The sustained-exposure dexamethasone formulation OTO-104 offers effective protection against cisplatin-induced hearing loss. Audiol Neurootol. 2016;21(1):22\u20139.","journal-title":"Audiol Neurootol"},{"issue":"6","key":"1312_CR65","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00280-011-1656-2","volume":"68","author":"CE Berglin","year":"2011","unstructured":"Berglin CE, et al. Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig model. Cancer Chemother Pharmacol. 2011;68(6):1547\u201356.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1312_CR66","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2352-4642(19)30115-4","volume":"3","author":"DR Freyer","year":"2019","unstructured":"Freyer DR, et al. Interventions for cisplatin-induced hearing loss in children and adolescents with cancer. Lancet Child Adolesc Health. 2019;3(8):578\u201384.","journal-title":"Lancet Child Adolesc Health"},{"issue":"5","key":"1312_CR67","first-page":"307","volume":"42","author":"AL Edmunds","year":"2017","unstructured":"Edmunds AL. Otiprio: an FDA-approved ciprofloxacin suspension gel for pediatric otitis media with effusion. P T. 2017;42(5):307\u201311.","journal-title":"P T"},{"key":"1312_CR68","unstructured":"Freyer DR DD, Orgel E et al. . Intratympanic injection of sustained-exposure dexamethasone thermosensitive gel (OTO-104) for prevention of cisplatin-induced hearing loss in children is feasible and safe. 2022(SIOP 2022 Annual Meeting Abstract 1172)."},{"issue":"10","key":"1312_CR69","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.2009.26.7872","volume":"28","author":"EA Neuwelt","year":"2010","unstructured":"Neuwelt EA, Brock P. Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol. 2010;28(10):1630\u20132.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1312_CR70","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1001\/jamaoncol.2021.2697","volume":"7","author":"AJM Meijer","year":"2021","unstructured":"Meijer AJM, et al. Recommendations for age-appropriate testing, timing, and frequency of audiologic monitoring during childhood cancer treatment: an International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA Oncol. 2021;7(10):1550\u20138.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1312_CR71","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/AUD.0b013e318228a77d","volume":"33","author":"N Beahan","year":"2012","unstructured":"Beahan N, et al. High-frequency pure-tone audiometry in children: a test-retest reliability study relative to ototoxic criteria. Ear Hear. 2012;33(1):104\u201311.","journal-title":"Ear Hear"},{"issue":"5","key":"1312_CR72","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3109\/00206099809072982","volume":"37","author":"W Reuter","year":"1998","unstructured":"Reuter W, et al. Extended high frequency audiometry in pre-school children. Audiology. 1998;37(5):285\u201394.","journal-title":"Audiology"},{"issue":"10","key":"1312_CR73","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/JCO.2006.07.9723","volume":"25","author":"KR Knight","year":"2007","unstructured":"Knight KR, et al. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;25(10):1190\u20135.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1312_CR74","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/pbc.24236","volume":"60","author":"AL Abujamra","year":"2013","unstructured":"Abujamra AL, et al. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy. Pediatr Blood Cancer. 2013;60(3):474\u20138.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"1312_CR75","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1200\/JCO.2016.69.2319","volume":"35","author":"KR Knight","year":"2017","unstructured":"Knight KR, et al. Group-wide, prospective study of ototoxicity assessment in children receiving cisplatin chemotherapy (ACCL05C1): a report from the Children\u2019s Oncology Group. J Clin Oncol. 2017;35(4):440\u20135.","journal-title":"J Clin Oncol"},{"key":"1312_CR76","unstructured":"Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy 1994 [Available from: https:\/\/www.asha.org\/policy\/gl1994-00003\/."},{"key":"1312_CR77","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) 2017 [updated November 27, 2017. 5.0:[Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"4","key":"1312_CR78","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/mpo.2950190415","volume":"19","author":"PR Brock","year":"1991","unstructured":"Brock PR, et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19(4):295\u2013300.","journal-title":"Med Pediatr Oncol"},{"issue":"10","key":"1312_CR79","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1200\/JCO.2009.24.4228","volume":"28","author":"KW Chang","year":"2010","unstructured":"Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol. 2010;28(10):1788\u201395.","journal-title":"J Clin Oncol"},{"issue":"sup4","key":"1312_CR80","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1080\/14992027.2017.1417644","volume":"57","author":"KA King","year":"2018","unstructured":"King KA, Brewer CC. Clinical trials, ototoxicity grading scales and the audiologist\u2019s role in therapeutic decision making. Int J Audiol. 2018;57(sup4):S89\u201398.","journal-title":"Int J Audiol"},{"issue":"4","key":"1312_CR81","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00106-005-1368-1","volume":"55","author":"CM Schmidt","year":"2007","unstructured":"Schmidt CM, et al. The \u201cMuenster classification\u201d of high frequency hearing loss following cisplatin chemotherapy. HNO. 2007;55(4):299\u2013306.","journal-title":"HNO"},{"issue":"2","key":"1312_CR82","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1055\/s-0039-1684043","volume":"40","author":"RE Gans","year":"2019","unstructured":"Gans RE, Rauterkus G, Research A. Vestibular toxicity: causes, evaluation protocols, intervention, and management. Semin Hear. 2019;40(2):144\u201353.","journal-title":"Semin Hear"},{"issue":"6","key":"1312_CR83","doi-asserted-by":"publisher","first-page":"e26992","DOI":"10.1002\/pbc.26992","volume":"65","author":"ML Camet","year":"2018","unstructured":"Camet ML, et al. Determining the prevalence of vestibular screening failures in pediatric cancer patients whose therapies include radiation to the head\/neck and platin-based therapies: a pilot study. Pediatr Blood Cancer. 2018;65(6):e26992.","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"1312_CR84","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1200\/JCO.22.00196","volume":"40","author":"AR Rosenberg","year":"2022","unstructured":"Rosenberg AR. We cannot change what we cannot see: a rationale for patient-reported outcomes in pediatric oncology clinical research. J Clin Oncol. 2022;40(15):1601\u20133.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1312_CR85","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(18)30895-7","volume":"20","author":"HM Katzenstein","year":"2019","unstructured":"Katzenstein HM, et al. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children\u2019s Oncology Group, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):719\u201327.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1312_CR86","doi-asserted-by":"publisher","first-page":"631","DOI":"10.5811\/westjem.2018.4.38383","volume":"19","author":"CE McCoy","year":"2018","unstructured":"McCoy CE. Understanding the use of composite endpoints in clinical trials. West J Emerg Med. 2018;19(4):631\u20134.","journal-title":"West J Emerg Med"},{"issue":"3","key":"1312_CR87","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.cmpb.2007.06.002","volume":"87","author":"O Kuss","year":"2007","unstructured":"Kuss O, McLerran D. A note on the estimation of the multinomial logistic model with correlated responses in SAS. Comput Methods Programs Biomed. 2007;87(3):262\u20139.","journal-title":"Comput Methods Programs Biomed"},{"issue":"5","key":"1312_CR88","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1121\/1.5132706","volume":"146","author":"RPC Cousins","year":"2019","unstructured":"Cousins RPC. Medicines discovery for auditory disorders: challenges for industry. J Acoust Soc Am. 2019;146(5):3652.","journal-title":"J Acoust Soc Am"}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-022-01312-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-022-01312-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-022-01312-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T07:21:36Z","timestamp":1716794496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11764-022-01312-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1007\/s11764-022-01312-x","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"3 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}